Il-1 binding proteins
AssigneeAbbVie Inc.
InventorsChengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
Life of this patent
Estimating the term…
Abstract
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.
Claims16
1-46. (canceled)
A method for reducing human IL-1 activity in a human subject suffering from a disorder in which the IL-1 activity is detrimental, comprising administering to the human subject a binding protein or a crystal thereof, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first heavy chain variable domain;
- VD2 is a second heavy chain variable domain;
- C is a heavy chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 is an Fc region;
- and
- n is independently 0 or 1;
- and
- wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first light chain variable domain;
- VD2 is a second light chain variable domain;
- C is a light chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 does not comprise an Fc region;
- and
- n is independently 0 or 1;
- wherein, in said first polypeptide chain, VD1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 60-148, 196, 198, 200, 202, 204, 206, 208 and 210;
- and VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 213 and 227;
- wherein, in said second polypeptide chain, VD1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 149-189, 197, 199, 201, 203, 205, 207, 209 and 211;
- and VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 216 and 229;
- and
- wherein the binding protein binds human IL-1β and human IL-1α, such that the human IL-1 activity in the human subject is reduced.
48-122. (canceled)
A method for reducing human IL-1 activity in a human subject suffering from a disorder in which the IL-1 activity is detrimental, comprising administering to the human subject a binding protein or a crystal thereof, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first heavy chain variable domain;
- VD2 is a second heavy chain variable domain;
- C is a heavy chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 is an Fc region;
- and
- n is independently 0 or 1;
- and
- wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first light chain variable domain;
- VD2 is a second light chain variable domain;
- C is a light chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 does not comprise an Fc region;
- and
- n is independently 0 or 1;
- wherein, in said first polypeptide chain, VD1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 213 and 227;
- and VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 60-148, 196, 198, 200, 202, 204, 206, 208 and 210;
- wherein, in said second polypeptide chain, VD1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 216 and 229;
- and VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 149-189, 197, 199, 201, 203, 205, 207, 209 and 211;
- and
- wherein the binding protein binds human IL-1β and human IL-1α, such that the human IL-1 activity is reduced.
Dependencies are inferred from the claim text.